瑞信升微创医疗(00853-HK)目标价至40港元维持跑输大市_老虎社区_美港股上老虎

瑞信升微创医疗(00853-HK)目标价至40港元维持跑输大市

财华社2021-04-07

原标题：瑞信升微创医疗(00853-HK)目标价至40港元维持跑输大市　　瑞信升微创医疗(00853-HK)目标价至40港元，维持跑输大市。　　该公司近日公布，截至2020年12月31日止年度，收入约为6.49亿美元，同比下降18.2%。股东应占亏损约为1.91亿美元，去年同期则溢利4628.1万美元。每股亏损10.97美分。　　该公司股价现报49.55港元，涨...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

AISA
·2021-04-13
瑞信，你这评测没有准过，别在这瞎扯了。
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2125712851?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/9880d7eec8b534b02eee516222413c4e","is_english":false,"pubTime":"2021-04-07 09:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2125712851","market":"hk","top_or_hot":-1,"title":"瑞信升微创医疗(00853-HK)目标价至40港元 维持跑输大市","media":"财华社","content":"<div>\n<p>原标题：瑞信升微创医疗(00853-HK)目标价至40港元 维持跑输大市\r\n            \n　　瑞信升微创医疗(00853-HK)目标价至40港元，维持跑输大市。\n　　该公司近日公布，截至2020年12月31日止年度，收入约为6.49亿美元，同比下降18.2%。股东应占亏损约为1.91亿美元，去年同期则溢利4628.1万美元。每股亏损10.97美分。\n　　该公司股价现报49.55港元，涨...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202104071874322845.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>瑞信升微创医疗(00853-HK)目标价至40港元 维持跑输大市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n瑞信升微创医疗(00853-HK)目标价至40港元 维持跑输大市\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-07 09:44 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202104071874322845.html><strong>财华社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>原标题：瑞信升微创医疗(00853-HK)目标价至40港元 维持跑输大市\r\n            \n　　瑞信升微创医疗(00853-HK)目标价至40港元，维持跑输大市。\n　　该公司近日公布，截至2020年12月31日止年度，收入约为6.49亿美元，同比下降18.2%。股东应占亏损约为1.91亿美元，去年同期则溢利4628.1万美元。每股亏损10.97美分。\n　　该公司股价现报49.55港元，涨...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202104071874322845.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00853","symbol_name":"微创医疗","start_time":0,"source_url":"http://finance.eastmoney.com/a/202104071874322845.html","article_id":"2125712851","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/9880d7eec8b534b02eee516222413c4e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2125712851","pubTimestamp":1617759840,"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"瑞信升微创医疗(00853-HK)目标价至40港元，维持跑输大市。该公司近日公布，截至2020年12月31日止年度，收入约为6.49亿美元，同比下降18.2%。股东应占亏损约为1.91亿美元，去年同期...","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"00853":"微创医疗"},"translate_title":"Credit Suisse rose to MicroPort Scientific (00853-HK) with a target price of HK $40 to maintain a loss in the market","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00853":1},"content_text":"原标题：瑞信升微创医疗(00853-HK)目标价至40港元 维持跑输大市\r\n            \n　　瑞信升微创医疗(00853-HK)目标价至40港元，维持跑输大市。\n　　该公司近日公布，截至2020年12月31日止年度，收入约为6.49亿美元，同比下降18.2%。股东应占亏损约为1.91亿美元，去年同期则溢利4628.1万美元。每股亏损10.97美分。\n　　该公司股价现报49.55港元，涨2.27%，成交量9.81万，成交额485.87万港元。（文章来源：财华社）\n\r\n                (责任编辑：DF545)","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[{"id":345800582,"gmtCreate":1618294290146,"gmtModify":1618294290146,"author":{"id":"3544614171973948","authorId":"3544614171973948","name":"AISA","avatar":"https://static.tigerbbs.com/845e65a439f350a55c2cbe79e4909162","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"瑞信，你这评测没有准过，别在这瞎扯了。","listText":"瑞信，你这评测没有准过，别在这瞎扯了。","text":"瑞信，你这评测没有准过，别在这瞎扯了。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/345800582","repostId":2125712851,"repostType":2,"repost":{"id":"2125712851","pubTimestamp":1617759840,"share":"https://www.laohu8.com/m/news/2125712851?lang=&edition=full","pubTime":"2021-04-07 09:44","market":"us","language":"zh","title":"瑞信升微创医疗(00853-HK)目标价至40港元 维持跑输大市","url":"https://stock-news.laohu8.com/highlight/detail?id=2125712851","media":"财华社","summary":"瑞信升微创医疗(00853-HK)目标价至40港元，维持跑输大市。该公司近日公布，截至2020年12月31日止年度，收入约为6.49亿美元，同比下降18.2%。股东应占亏损约为1.91亿美元，去年同期...","content":"<html><body><div>\n<p>\r\n                原标题：瑞信升<a href=\"https://laohu8.com/S/00853\">微创医疗</a>(00853-HK)目标价至40港元 维持跑输大市\r\n            </p>\n<p><img border=\"0\" height=\"276\" src=\"https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=116.00853&amp;imageType=k&amp;token=28dfeb41d35cc81d84b4664d7c23c49f&amp;at=1\" width=\"578\"/></p><p>　　瑞信升<span>微创医疗</span>(00853-HK)目标价至40港元，维持跑输大市。</p><div></div>\n<p>　　该公司近日公布，截至2020年12月31日止年度，收入约为6.49亿美元，同比下降18.2%。<span>股东</span>应占亏损约为1.91亿美元，去年同期则溢利4628.1万美元。每股亏损10.97美分。</p>\n<p>　　该公司股价现报49.55港元，涨2.27%，成交量9.81万，成交额485.87万港元。</p><p>（文章来源：财华社）</p>\n<p>\r\n                (责任编辑：DF545)\r\n            </p>\n</div></body></html>","source":"stock_eastmoney","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>瑞信升微创医疗(00853-HK)目标价至40港元 维持跑输大市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n瑞信升微创医疗(00853-HK)目标价至40港元 维持跑输大市\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-07 09:44 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202104071874322845.html><strong>财华社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>原标题：瑞信升微创医疗(00853-HK)目标价至40港元 维持跑输大市\r\n            \n　　瑞信升微创医疗(00853-HK)目标价至40港元，维持跑输大市。\n　　该公司近日公布，截至2020年12月31日止年度，收入约为6.49亿美元，同比下降18.2%。股东应占亏损约为1.91亿美元，去年同期则溢利4628.1万美元。每股亏损10.97美分。\n　　该公司股价现报49.55港元，涨...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202104071874322845.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/9880d7eec8b534b02eee516222413c4e","relate_stocks":{"00853":"微创医疗"},"source_url":"http://finance.eastmoney.com/a/202104071874322845.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2125712851","content_text":"原标题：瑞信升微创医疗(00853-HK)目标价至40港元 维持跑输大市\r\n            \n　　瑞信升微创医疗(00853-HK)目标价至40港元，维持跑输大市。\n　　该公司近日公布，截至2020年12月31日止年度，收入约为6.49亿美元，同比下降18.2%。股东应占亏损约为1.91亿美元，去年同期则溢利4628.1万美元。每股亏损10.97美分。\n　　该公司股价现报49.55港元，涨2.27%，成交量9.81万，成交额485.87万港元。（文章来源：财华社）\n\r\n                (责任编辑：DF545)","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}